Sign In

Login

Password

Forgot Password ? Sign Up

Semaglutid (German Wikipedia)

Analysis of information sources in references of the Wikipedia article "Semaglutid" in German language version.

refsWebsite
Global rank German rank
24doi.org
2nd place
3rd place
23nih.gov
4th place
7th place
11europa.eu
68th place
29th place
6fda.gov
447th place
751st place
2who.int
195th place
255th place
2elsevier.com
610th place
521st place
1biosynth.com
low place
low place
1hres.ca
low place
low place
1pmda.go.jp
6,690th place
low place
1akdae.de
low place
1,853rd place
1aerzteblatt.de
3,043rd place
200th place
1g-ba.de
low place
1,618th place
1morgenpost.de
1,433rd place
86th place
1pharmazeutische-zeitung.de
8,614th place
583rd place
1aerztezeitung.de
low place
711th place
1baden-wuerttemberg.de
3,471st place
257th place
1web.archive.org
1st place
1st place
1redirecter.toolforge.org
33rd place
2nd place
1tagesschau.de
884th place
51st place
1nytimes.com
7th place
19th place
1orf.at
418th place
22nd place
1aktienwelt360.de
low place
low place

aerzteblatt.de (Global: 3,043rd place; German: 200th place)

aerztezeitung.de (Global: low place; German: 711th place)

akdae.de (Global: low place; German: 1,853rd place)

aktienwelt360.de (Global: low place; German: low place)

baden-wuerttemberg.de (Global: 3,471st place; German: 257th place)

rp.baden-wuerttemberg.de

biosynth.com (Global: low place; German: low place)

doi.org (Global: 2nd place; German: 3rd place)

  • S. Kalra, Y. Gupta: Abstracts of the 48th EASD (European Association for the Study of Diabetes) Annual Meeting of the European Association for the Study of Diabetes. October 1-5, 2012. Berlin, Germany. In: Diabetologia, Band 55 Suppl 1, Oktober 2012, S. S7–537, doi:10.1007/s00125-012-2688-9, PMID 22918257.
  • RM Goldenberg, O Steen: Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes. In: Canadian Journal of Diabetes. 43. Jahrgang, Nr. 2, März 2019, S. 136–145, doi:10.1016/j.jcjd.2018.05.008, PMID 30195966 (englisch).
  • C Kapitza, L Nosek, L Jensen, H Hartvig, CB Jensen, A Flint: Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. In: Journal of Clinical Pharmacology. 55. Jahrgang, Nr. 5, Mai 2015, S. 497–504, doi:10.1002/jcph.443, PMID 25475122, PMC 4418331 (freier Volltext) – (englisch).
  • H. A. Alsugair, I. F. Alshugair, T. J. Alharbi, A. M. Bin Rsheed, A. M. Tourkmani, W. Al-Madani: Weekly Semaglutide vs. Liraglutide Efficacy Profile: A Network Meta-Analysis. In: Healthcare, Band 9, Nummer 9, August 2021; doi:10.3390/healthcare9091125, PMID 34574899, PMC 8466858 (freier Volltext).
  • Y. Deng, A. Park, L. Zhu, W. Xie, C. Q. Pan: Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review. In: Therapeutic advances in chronic disease. Band 13, 2022, S. 20406223221108064; doi:10.1177/20406223221108064, PMID 35813188, PMC 9260566 (freier Volltext).
  • H. N. Jung, C. H. Jung: The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS? In: Journal of obesity & metabolic syndrome, Band 31, Nummer 1, März 2022. S. 28–36; doi:10.7570/jomes22012, PMID 35314521, PMC 8987449 (freier Volltext).
  • T. D. Müller, M. Blüher, M. H. Tschöp, R. D. DiMarchi: Anti-obesity drug discovery: advances and challenges. In: Nature Reviews Drug Discovery, Band 21, Nummer 3, März 2022, S. 201–223; doi:10.1038/s41573-021-00337-8, PMID 34815532, PMC 8609996 (freier Volltext).
  • S. S. Lee, S. H. Park: Radiologic evaluation of nonalcoholic fatty liver disease. In: World Journal of Gastroenterology, Band 20, Heft 23, 2014. S. 7392–7402. doi:10.3748/wjg.v20.i23.7392. PMID 24966609. PMC 4064084 (freier Volltext).
  • Deep Dutta, Manoj Kumar, K.S. Shivaprasad, Ashok Kumar, Meha Sharma: Impact of semaglutide on biochemical and radiologic measures of metabolic-dysfunction associated fatty liver disease across the spectrum of glycaemia: A meta-analysis. In: Diabetes and Metabolic Syndrome: Clinical Research and Reviews, Band 16, Nummer 6, 2022. S. 102539; doi:10.1016/j.dsx.2022.102539. PMID 35709586.
  • F. G. Eliaschewitz, L. H. Canani: Advances in GLP-1 treatment: focus on oral semaglutide. In: Diabetology & Metabolic Syndrome, Band 13, Nummer 1, September 2021. S. 99; doi:10.1186/s13098-021-00713-9, PMID 34526121, PMC 8442336 (freier Volltext) (Review).
  • A. M. Chao, J. S. Tronieri, A. Amaro, T. A. Wadden: Semaglutide for the treatment of obesity. In: Trends in cardiovascular medicine, Band 33, Nummer 3, April 2023. S. 159–166; doi:10.1016/j.tcm.2021.12.008, PMID 34942372, PMC 9209591 (freier Volltext).
  • S. Fattah, M. Ismaiel, B. Murphy, A. Rulikowska, J. M. Frias, D. C. Winter, D. J. Brayden: Salcaprozate sodium (SNAC) enhances permeability of octreotide across isolated rat and human intestinal epithelial mucosae in Ussing chambers. In: European journal of pharmaceutical sciences: official journal of the European Federation for Pharmaceutical Sciences, Band 154, November 2020. S. 105509; doi:10.1016/j.ejps.2020.105509, PMID 32777258.
  • Benjamin M. Scirica, A. Michael Lincoff, Ildiko Lingvay, Pawel Bogdanski, Silvio Buscemi, Helen Colhoun, Anca-Elena Craciun, Marat Ezhov, Søren Hardt-Lindberg, Ole Kleist Jeppesen, Ana Laura S.A. Matos, Koichi Node, Francois Schiele, Hermann Toplak, André van Beek, Peter E. Weeke, Stephen D. Wiviott, John Deanfield, Donna Ryan: The Effect of Semaglutide on Mortality and COVID-19–Related Deaths. In: Journal of the American College of Cardiology. August 2024, doi:10.1016/j.jacc.2024.08.007 (elsevier.com [abgerufen am 31. August 2024]).
  • Jeremy Samuel Faust: Semaglutide, COVID-19 Mortality, and the Power of Harnessing Ongoing Clinical Trials During Unexpected Outbreaks. In: Journal of the American College of Cardiology. August 2024, doi:10.1016/j.jacc.2024.08.035 (elsevier.com [abgerufen am 31. August 2024]).
  • L. B. Knudsen, J. Lau: The Discovery and Development of Liraglutide and Semaglutide. In: Frontiers in Endocrinology, Band 10, 2019. S. 155. doi:10.3389/fendo.2019.00155, PMID 31031702, PMC 6474072 (freier Volltext).
  • J. Lau, P. Bloch, L. Schäffer, I. Pettersson, J. Spetzler, J. Kofoed, K. Madsen, L. B. Knudsen, J. McGuire, D. B. Steensgaard, H. M. Strauss, D. X. Gram, S. M. Knudsen, F. S. Nielsen, P. Thygesen, S. Reedtz-Runge, T. Kruse: Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. In: Journal of Medicinal Chemistry, Band 58, Nummer 18, September 2015. S. 7370–7380; doi:10.1021/acs.jmedchem.5b00726, PMID 26308095.
  • C. F. Gotfredsen, A. M. Mølck, I. Thorup, N. C. Nyborg, Z. Salanti, L. B. Knudsen, M. O. Larsen: The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates. In: Diabetes, Band 63, Nummer 7, Juli 2014. S. 2486–2497; doi:10.2337/db13-1087, PMID 24608440.
  • A. Bikou, F. Dermiki-Gkana, M. Penteris, T. K. Constantinides, C. Kontogiorgis: A systematic review of the effect of semaglutide on lean mass: insights from clinical trials. In: Expert opinion on pharmacotherapy. Band 25, Nummer 5, April 2024, S. 611–619, doi:10.1080/14656566.2024.2343092, PMID 38629387.
  • D. Rubino et al.: Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. Journal of the American Medical Association (JAMA), 2021. doi:10.1001/jama.2021.3224
  • L. Barbagelata, W. Masson, M. Lobo, I. Bluro: Semaglutide and heart failure: Updated meta-analysis. In: Current problems in cardiology. Band 49, Nummer 9, September 2024, S. 102721, doi:10.1016/j.cpcardiol.2024.102721, PMID 38908729.
  • A. Saglietto, G. Falasconi, D. Penela, P. Francia, A. Sau, F. S. Ng, V. Dusi, D. Castagno, F. Gaita, A. Berruezo, G. M. De Ferrari, M. Anselmino: Glucagon-like peptide-1 receptor agonist semaglutide reduces atrial fibrillation incidence: A systematic review and meta-analysis. In: European journal of clinical investigation. Band 54, Nummer 12, Dezember 2024, S. e14292, doi:10.1111/eci.14292, PMID 39058274.
  • H. D. Zhang, L. Ding, K. Liu, L. J. Mi, A. K. Zhang, F. Y. Yu, X. X. Yan, F. H. Peng, Y. J. Shen, M. Tang: Semaglutide for the prevention of atrial fibrillation: A systematic review and meta-analysis. In: Diabetes & metabolic syndrome. Band 18, Nummer 6, Juni 2024, S. 103067, doi:10.1016/j.dsx.2024.103067, PMID 38955095.
  • Sanjay Bandyopadhyay, Saibal Das, Shambo Samrat Samajdar, Shashank Joshi: Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis. In: Diabetes & Metabolic Syndrome Clinical Research & Reviews. 2023, Band 17, Nummer 10, S. 102849 doi:10.1016/j.dsx.2023.102849.
  • Danny Issa, Philip N. Newsome, Iris Kliers, Laura Østergaard, Michelle T. Long, Mette Skalshøi Kjær, Anna M.G. Cali, Elisabetta Bugianesi, Mary E. Rinella, Michael Roden, Vlad Ratziu: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis. In: New England Journal of Medicine. 2025. doi:10.1056/NEJMoa2413258.

elsevier.com (Global: 610th place; German: 521st place)

linkinghub.elsevier.com

  • Benjamin M. Scirica, A. Michael Lincoff, Ildiko Lingvay, Pawel Bogdanski, Silvio Buscemi, Helen Colhoun, Anca-Elena Craciun, Marat Ezhov, Søren Hardt-Lindberg, Ole Kleist Jeppesen, Ana Laura S.A. Matos, Koichi Node, Francois Schiele, Hermann Toplak, André van Beek, Peter E. Weeke, Stephen D. Wiviott, John Deanfield, Donna Ryan: The Effect of Semaglutide on Mortality and COVID-19–Related Deaths. In: Journal of the American College of Cardiology. August 2024, doi:10.1016/j.jacc.2024.08.007 (elsevier.com [abgerufen am 31. August 2024]).
  • Jeremy Samuel Faust: Semaglutide, COVID-19 Mortality, and the Power of Harnessing Ongoing Clinical Trials During Unexpected Outbreaks. In: Journal of the American College of Cardiology. August 2024, doi:10.1016/j.jacc.2024.08.035 (elsevier.com [abgerufen am 31. August 2024]).

europa.eu (Global: 68th place; German: 29th place)

ema.europa.eu

ec.europa.eu

fda.gov (Global: 447th place; German: 751st place)

accessdata.fda.gov

fda.gov

g-ba.de (Global: low place; German: 1,618th place)

hres.ca (Global: low place; German: low place)

hpr-rps.hres.ca

morgenpost.de (Global: 1,433rd place; German: 86th place)

nih.gov (Global: 4th place; German: 7th place)

ncbi.nlm.nih.gov

  • S. Kalra, Y. Gupta: Abstracts of the 48th EASD (European Association for the Study of Diabetes) Annual Meeting of the European Association for the Study of Diabetes. October 1-5, 2012. Berlin, Germany. In: Diabetologia, Band 55 Suppl 1, Oktober 2012, S. S7–537, doi:10.1007/s00125-012-2688-9, PMID 22918257.
  • RM Goldenberg, O Steen: Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes. In: Canadian Journal of Diabetes. 43. Jahrgang, Nr. 2, März 2019, S. 136–145, doi:10.1016/j.jcjd.2018.05.008, PMID 30195966 (englisch).
  • C Kapitza, L Nosek, L Jensen, H Hartvig, CB Jensen, A Flint: Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. In: Journal of Clinical Pharmacology. 55. Jahrgang, Nr. 5, Mai 2015, S. 497–504, doi:10.1002/jcph.443, PMID 25475122, PMC 4418331 (freier Volltext) – (englisch).
  • H. A. Alsugair, I. F. Alshugair, T. J. Alharbi, A. M. Bin Rsheed, A. M. Tourkmani, W. Al-Madani: Weekly Semaglutide vs. Liraglutide Efficacy Profile: A Network Meta-Analysis. In: Healthcare, Band 9, Nummer 9, August 2021; doi:10.3390/healthcare9091125, PMID 34574899, PMC 8466858 (freier Volltext).
  • Y. Deng, A. Park, L. Zhu, W. Xie, C. Q. Pan: Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review. In: Therapeutic advances in chronic disease. Band 13, 2022, S. 20406223221108064; doi:10.1177/20406223221108064, PMID 35813188, PMC 9260566 (freier Volltext).
  • H. N. Jung, C. H. Jung: The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS? In: Journal of obesity & metabolic syndrome, Band 31, Nummer 1, März 2022. S. 28–36; doi:10.7570/jomes22012, PMID 35314521, PMC 8987449 (freier Volltext).
  • PMC 3402009 (freier Volltext) Comparison with ancestral diets suggests dense acellular carbohydrates promote an inflammatory microbiota, and may be the primary dietary cause of leptin resistance and obesity
  • T. D. Müller, M. Blüher, M. H. Tschöp, R. D. DiMarchi: Anti-obesity drug discovery: advances and challenges. In: Nature Reviews Drug Discovery, Band 21, Nummer 3, März 2022, S. 201–223; doi:10.1038/s41573-021-00337-8, PMID 34815532, PMC 8609996 (freier Volltext).
  • S. S. Lee, S. H. Park: Radiologic evaluation of nonalcoholic fatty liver disease. In: World Journal of Gastroenterology, Band 20, Heft 23, 2014. S. 7392–7402. doi:10.3748/wjg.v20.i23.7392. PMID 24966609. PMC 4064084 (freier Volltext).
  • Deep Dutta, Manoj Kumar, K.S. Shivaprasad, Ashok Kumar, Meha Sharma: Impact of semaglutide on biochemical and radiologic measures of metabolic-dysfunction associated fatty liver disease across the spectrum of glycaemia: A meta-analysis. In: Diabetes and Metabolic Syndrome: Clinical Research and Reviews, Band 16, Nummer 6, 2022. S. 102539; doi:10.1016/j.dsx.2022.102539. PMID 35709586.
  • F. G. Eliaschewitz, L. H. Canani: Advances in GLP-1 treatment: focus on oral semaglutide. In: Diabetology & Metabolic Syndrome, Band 13, Nummer 1, September 2021. S. 99; doi:10.1186/s13098-021-00713-9, PMID 34526121, PMC 8442336 (freier Volltext) (Review).
  • A. M. Chao, J. S. Tronieri, A. Amaro, T. A. Wadden: Semaglutide for the treatment of obesity. In: Trends in cardiovascular medicine, Band 33, Nummer 3, April 2023. S. 159–166; doi:10.1016/j.tcm.2021.12.008, PMID 34942372, PMC 9209591 (freier Volltext).
  • S. Fattah, M. Ismaiel, B. Murphy, A. Rulikowska, J. M. Frias, D. C. Winter, D. J. Brayden: Salcaprozate sodium (SNAC) enhances permeability of octreotide across isolated rat and human intestinal epithelial mucosae in Ussing chambers. In: European journal of pharmaceutical sciences: official journal of the European Federation for Pharmaceutical Sciences, Band 154, November 2020. S. 105509; doi:10.1016/j.ejps.2020.105509, PMID 32777258.
  • Semaglutide. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet], National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda MD, 2019; PMID 31643889.
  • L. B. Knudsen, J. Lau: The Discovery and Development of Liraglutide and Semaglutide. In: Frontiers in Endocrinology, Band 10, 2019. S. 155. doi:10.3389/fendo.2019.00155, PMID 31031702, PMC 6474072 (freier Volltext).
  • J. Lau, P. Bloch, L. Schäffer, I. Pettersson, J. Spetzler, J. Kofoed, K. Madsen, L. B. Knudsen, J. McGuire, D. B. Steensgaard, H. M. Strauss, D. X. Gram, S. M. Knudsen, F. S. Nielsen, P. Thygesen, S. Reedtz-Runge, T. Kruse: Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. In: Journal of Medicinal Chemistry, Band 58, Nummer 18, September 2015. S. 7370–7380; doi:10.1021/acs.jmedchem.5b00726, PMID 26308095.
  • C. F. Gotfredsen, A. M. Mølck, I. Thorup, N. C. Nyborg, Z. Salanti, L. B. Knudsen, M. O. Larsen: The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates. In: Diabetes, Band 63, Nummer 7, Juli 2014. S. 2486–2497; doi:10.2337/db13-1087, PMID 24608440.
  • A. Bikou, F. Dermiki-Gkana, M. Penteris, T. K. Constantinides, C. Kontogiorgis: A systematic review of the effect of semaglutide on lean mass: insights from clinical trials. In: Expert opinion on pharmacotherapy. Band 25, Nummer 5, April 2024, S. 611–619, doi:10.1080/14656566.2024.2343092, PMID 38629387.
  • L. Barbagelata, W. Masson, M. Lobo, I. Bluro: Semaglutide and heart failure: Updated meta-analysis. In: Current problems in cardiology. Band 49, Nummer 9, September 2024, S. 102721, doi:10.1016/j.cpcardiol.2024.102721, PMID 38908729.
  • A. Saglietto, G. Falasconi, D. Penela, P. Francia, A. Sau, F. S. Ng, V. Dusi, D. Castagno, F. Gaita, A. Berruezo, G. M. De Ferrari, M. Anselmino: Glucagon-like peptide-1 receptor agonist semaglutide reduces atrial fibrillation incidence: A systematic review and meta-analysis. In: European journal of clinical investigation. Band 54, Nummer 12, Dezember 2024, S. e14292, doi:10.1111/eci.14292, PMID 39058274.
  • H. D. Zhang, L. Ding, K. Liu, L. J. Mi, A. K. Zhang, F. Y. Yu, X. X. Yan, F. H. Peng, Y. J. Shen, M. Tang: Semaglutide for the prevention of atrial fibrillation: A systematic review and meta-analysis. In: Diabetes & metabolic syndrome. Band 18, Nummer 6, Juni 2024, S. 103067, doi:10.1016/j.dsx.2024.103067, PMID 38955095.

dailymed.nlm.nih.gov

nytimes.com (Global: 7th place; German: 19th place)

orf.at (Global: 418th place; German: 22nd place)

pharmazeutische-zeitung.de (Global: 8,614th place; German: 583rd place)

pmda.go.jp (Global: 6,690th place; German: low place)

redirecter.toolforge.org (Global: 33rd place; German: 2nd place)

  • BfArM - Fälschung des Arzneimittels Ozempic®. Archiviert vom Original am 22. Dezember 2024; abgerufen am 30. Januar 2025.

tagesschau.de (Global: 884th place; German: 51st place)

web.archive.org (Global: 1st place; German: 1st place)

  • BfArM - Fälschung des Arzneimittels Ozempic®. Archiviert vom Original am 22. Dezember 2024; abgerufen am 30. Januar 2025.

who.int (Global: 195th place; German: 255th place)